KTX-1029 / K36 Therap - LARVOL DELTA

Ktx-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4; 14) Multiple Myeloma Preclinical Models (ASH 2024) - P1 | "The KMS11/BTZ line is also cross-resistant to carfilzomib and addition of KTX-1029 to carfilzomib resulted in synergistic inhibition of cell viability (IC50 : carfilzomib alone=15.27 nM, KTX-1029 alone=5104 nM, 1000 nM KTX-1029+bortezomib= 7.87 nM). KTX-1029 compliments the orally-available clinical candidate, KTX-1001 that is being evaluated in an ongoing clinical trial for relapsed/refractory MM patients. Preclinical data with KTX-1029 adds to the body of evidence for targeting MMSET in MM patients with t(4; 14) and for further exploration of combination regimens with MM standards of care."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • IGH • NSD2

K36 Therapeutics Announces Multiple Poster Presentations Highlighting…Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting (PRNewswire) - "Describes the in vitro and in vivo efficacy of KTX-1029, a novel, potent, selective inhibitor of MMSET. KTX-1029 demonstrated efficacy in MM preclinical models as a single agent and in combination with the proteasome inhibitors bortezomib and carfilzomib in both PI-sensitive and -resistant settings; The data generated with KTX-1029 compliments the data generated with the company's orally-available clinical candidate, KTX-1001 and adds to the body of evidence for targeting MMSET in multiple myeloma patients with t(4;14) and for further exploration of combination regimens with multiple myeloma standards of care."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology